Ross C. Overman
Norwich Research Park
Norwich, ENG, United Kingdom
Norwich, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles.
Journal: iScience
Published: November 17, 2023
Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy.
Journal: Journal of medicinal chemistry
Published: March 08, 2021
Engineered Cas9 extracellular vesicles as a novel gene editing tool.
Journal: Journal of extracellular vesicles
Published: February 23, 2021
A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding.
Journal: The Biochemical journal
Published: September 11, 2020
Structural and binding characterization of the LacdiNAc-specific adhesin (LabA; HopD) exodomain from Helicobacter pylori.
Journal: Current research in structural biology
Published: August 24, 2020
Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice.
Journal: Plant biotechnology journal
Published: May 05, 2020
Endosomal escape enhancing compounds facilitate functional delivery of extracellular vesicle cargo.
Journal: Nanomedicine (London, England)
Published: November 15, 2019
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Journal: Science translational medicine
Published: August 24, 2019
Introduction of a C-terminal hexa-lysine tag increases thermal stability of the LacDiNac binding adhesin (LabA) exodomain from Helicobacter pylori.
Journal: Protein expression and purification
Published: May 15, 2019
KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe.
Journal: Nature communications
Published: October 16, 2018
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.
Journal: Journal of medicinal chemistry
Published: September 12, 2018
Last Updated: 09/26/2026